Author/Authors :
Perreault, Martin Laboratory of Molecular Pharmacology - CHU-Quebec Research Centre and the Faculty of Pharmacy - Laval University, Quebec City, Canada , Wunsch, Ewa Translation Medicine Group - Pomeranian Medical University, Szczecin, Poland , BiaBek, Andrzej Translation Medicine Group - Pomeranian Medical University, Szczecin, Poland , Trottier, Jocelyn Laboratory of Molecular Pharmacology - CHU-Quebec Research Centre and the Faculty of Pharmacy - Laval University, Quebec City, Canada , Verreault, Mélanie Laboratory of Molecular Pharmacology - CHU-Quebec Research Centre and the Faculty of Pharmacy - Laval University, Quebec City, Canada , Caron, Patrick Laboratory of Molecular Pharmacology - CHU-Quebec Research Centre and the Faculty of Pharmacy - Laval University, Quebec City, Canada , Poirier, Guy G Proteomics Platform - Quebec Genomic Center - CHU-Qu ebec Research Centre and Faculty of Medicine - Laval University, Quebec City, Canada , Milkiewicz, Piotr Liver and Internal Medicine - Medical University of Warsaw, Warsaw, Poland , Barbier, Olivier Laboratory of Molecular Pharmacology - CHU-Quebec Research Centre and the Faculty of Pharmacy - Laval University, Quebec City, Canada
Abstract :
Biliary obstruction, a severe cholestatic complication, causes accumulation of toxic bile acids (BAs) in liver cells. Glucuronidation, catalyzed by UDP-glucuronosyltransferase (UGT) enzymes, detoxifies cholestatic BAs. Using liquid chromatography coupled to tandem mass spectrometry, 11 BA glucuronide (-G) species were quantified in prebiliary and postbiliary stenting serum and urine samples from 17 patients with biliary obstruction. Stenting caused glucuronide- and fluid-specific changes in BA-G levels and BA-G/BA metabolic ratios. In vitro glucuronidation assays with human liver and kidney microsomes revealed that even if renal enzymes generally displayed lower KM values, the two tissues shared similar glucuronidation capacities for BAs. By contrast, major differences between the two tissues were observed when four human BA-conjugating UGTs 1A3, 1A4, 2B4, and 2B7 were analyzed for mRNA and protein levels. Notably, the BA-24G producing UGT1A3 enzyme, abundant in the liver, was not detected in kidney microsomes. In conclusion, the circulating and urinary BA-G profiles are hugely impacted under severe cholestasis. The similar BA-glucuronidating abilities of hepatic and renal extracts suggest that both the liver and kidney may contribute to the urine BA-G pool.
Keywords :
Urinary Elimination , Bile Acid Glucuronides , Cholestatic Situations , Hepatic , Renal Glucuronidation Reactions